<DOC>
	<DOCNO>NCT01520116</DOCNO>
	<brief_summary>This randomize dose-ranging study evaluate safety , tolerability , preliminary efficacy ( reduction intraocular pressure ) multiple dose level ATS907 , vehicle , latanoprost subject primary open angle glaucoma ocular hypertension . In first portion , approximately 75 subject randomize receive either ATS907 vehicle eye drop 28 day , administer twice daily . In second portion , 180 subject randomize receive either ATS907 latanoprost 28 day . Plasma pharmacokinetics also evaluate first portion study .</brief_summary>
	<brief_title>Study Safety Efficacy ATS907 Subjects With Primary Open Angle Glaucoma ( POAG ) Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>18 year age great Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) eye Unmedicated ( postwashout ) IOP ≥ 23 mm Hg 2 eligibility visit : 07:0009:00 hr Days O 1 IOP &gt; 18 mm Hg 15:0017:00 Day 0 ( Stage 1 ) Unmedicated ( postwashout ) IOP criterion wash &lt; 32 mm Hg OU time point ( Stage 1 ) Unmedicated ( postwashout ) IOP ≥ 24 mm Hg 2 eligibility visit : 07:0009:00 hr Days O 1 IOP &gt; 21 mm Hg 9:0017:00 Day 0 ( Stage 2 ) Unmedicated ( postwashout ) IOP criterion wash &lt; 36 mm Hg OU time point ( Stage 2 ) Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) Must willing discontinue use ocular hypotensive medication eye prior entire course study Ophthalmic ( either eye ) 1 . Glaucoma : pseudoexfoliation , steroid induce , pigment dispersion glaucoma , history angle closure . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . Prior laser glaucoma surgery permit non study eye 2 . Refractive surgery study eye ( e.g. , radial keratotomy , PRK , LASIK , etc . ) 3 . Cataract surgery intraocular surgery within three month prior Screening either eye . 4 . History within 3 month prior Screening clinically significant moderate severe chronic active ocular infection , inflammation , blepharitis , dermatitis , uveitis conjunctivitis . 5 . Clinically significant corneal dystrophy , epithelial endothelial disease , corneal irregularity scar reliable applanation tonometry would prevent . 6 . Contact lens wear duration study . 7 . Clinically significant ocular disease ( e.g . diabetic retinopathy , macular degeneration , uveitis ) might interfere progress study . 8 . Central corneal thickness &lt; 480 &gt; 600 μm study eye Systemic 1 . Clinically significant abnormality laboratory test screen . 2 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , uncontrolled hyper hypotension , hepatic , renal , endocrine cardiovascular disorder ) . Participation investigational study within past 30 day . 3 . Changes systemic medication could substantial effect IOP systemic blood pressure within 7 day prior Baseline ( Day 0 ) . 4 . Women childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result Screening visit negative urine serum pregnancy Baseline ( Day 0 ) must intend become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>